Immix Biopharma, Inc. (IMMX)
NASDAQ: IMMX · Real-Time Price · USD
1.700
+0.110 (6.92%)
Nov 18, 2024, 2:15 PM EST - Market open
Immix Biopharma Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Immix Biopharma stock has a target of 7.00, which predicts an increase of 311.76% from the current stock price of 1.70.
Analyst Consensus: Strong Buy
* Price targets were last updated on Oct 3, 2024.
Analyst Ratings
According to 1 stock analyst, the rating for IMMX is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 2 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 1 | 2 | 1 | 1 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +311.76% | Oct 3, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +311.76% | Aug 19, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +311.76% | Jul 26, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +311.76% | Jul 9, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +311.76% | Jul 1, 2024 |
Financial Forecast
Revenue This Year
1.02M
Revenue Next Year
3.06M
from 1.02M
Increased by 200.00%
EPS This Year
-0.65
from -0.89
EPS Next Year
-0.56
from -0.65
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 2.1M | 6.3M | 12.7M | ||
| Avg | 1.0M | 3.1M | 12.4M | ||
| Low | n/a | n/a | 11.9M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 517.6% | 316.6% | ||
| Avg | - | 200.0% | 304.7% | ||
| Low | - | - | 288.8% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.64 | -0.55 | -0.39 | ||
| Avg | -0.65 | -0.56 | -0.38 | ||
| Low | -0.66 | -0.57 | -0.36 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.